This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2B3-201

BBB Therapeutics B.V.

Drug Names(s): Glutathione PEGylated Liposomal Methylprednisolone

Description: 2B3-201, a glutathione PEGylated liposomal methylprednisolone, acts on neuroinflammation through the Company's proprietary G-Technology delivery system.

Deal Structure: In September 2014, to-BBB announced significant additions to complete its new management team as well as changing its name from to-BBB technologies B.V. to BBB Therapeutics B.V.

2B3-201 News

Pink Sheet Global Pharma Guidance Tracker – November 2018

Scrip Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma

Scrip Venture Funding Deals: Gotham Raises $54m To Advance Epitranscriptomics

Scrip Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug